Person:
ATAGÜNDÜZ, MEHMET PAMİR

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ATAGÜNDÜZ

First Name

MEHMET PAMİR

Name

Filters

20232
Reset filters

Settings

Author: ABACAR, KEREM YİĞİT × Subject: Health Sciences ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Exosomes' profile in ankylosing spondylitis: A preliminary study
    (2023-01-01) ABACAR, KEREM YİĞİT; ATAGÜNDÜZ, MEHMET PAMİR; ERZİK, CAN; Karakaya E., Deniz R., ABACAR K. Y., ATAGÜNDÜZ M. P., ERZİK C.
    Objective: Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that leads to structural and functional im-pairments and reduced quality of life, with heterogeneous manifestations. The origin and possible role of extracellular vesicles represented by exosomes (EVexo) in the pathogenesis of AS were examined in this study. Materials and Methods: Extracellular vesicles (EVs) were isolated from serum from ten AS patients and ten healthy controls through Izon qEV2/35 nm columns. After assessing the isolate purity by bicinchoninic acid assay (BCA) and Enzyme-Linked ImmunoSorbent Assay (ELISA), the relationship between EVexo concentration and AS was tested by the BCA method. The EVexo surface markers were analyzed by flow cytometry (FC) to verify EVexo presence and reveal its origin. Results: In FC analysis, CD86+TSG101+ and CD3+TSG101+ exosome percentages of AS group were significantly higher than the control group (p<0.05). A significant difference was found between the AS and control groups in terms of CD3+IL17+ and CD3+IFNg+ and CD86+TNF alpha+ and CD86+IL12(p35)+ exosome percentages (p<0.01). Conclusion: The exosomes whose ratio increased in the AS process were derived from T cells expressing increased levels of IL-17A and IFNg in their membranes, and macrophages expressing increased levels of TNF alpha and IL-12(p35) in their membranes. The EVexo profile did not change according to the AS course.
  • Thumbnail Image
    PublicationOpen Access
    Re: Risk of hbv reactivation in hbsag negative and antihbc igg positive patients receiving biologic therapy
    (2023-03-01) KANİ, HALUK TARIK; KARABACAK, MURAT; CÖMERT ÖZER, ELİF; ABACAR, KEREM YİĞİT; KUTLUĞ AĞAÇKIRAN, SEDA; SEVİK, GİZEM; ALİBAZ ÖNER, FATMA; İNANÇ, GÜZİDE NEVSUN; ATAGÜNDÜZ, MEHMET PAMİR; ÖZEN ALAHDAB, YEŞİM; DİRESKENELİ, RAFİ HANER; ATUĞ, ÖZLEN; Ergenç İ., KANİ H. T., KARABACAK M., CÖMERT ÖZER E., Mehdiyev S., Jafarov F., ABACAR K. Y., KUTLUĞ AĞAÇKIRAN S., SEVİK G., Aslan R., et al.